Lithium Isonicotinamide Co-crystals for Reduced Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lithium treatments for depressive diseases have significant side effects such as lithium toxicity, due to a poorly suited pharmacokinetic profile, and a narrow therapeutic window, leading to high toxicity and reduced compliance.
Innovation Solution
Development of stable solid forms of lithium, specifically crystalline forms of organic acid salts of lithium, which exhibit improved stability and brain bioavailability, potentially reducing toxicity and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lithium carbonate or lithium citrate is used as drug substance, then lithium therapy can be provided, but the compounds have narrow therapeutic window and high toxicity
Solution Approach 1:
The patent changes the chemical form of lithium from conventional carbonate or citrate salts to novel crystalline co-crystal forms with specific organic acids. This parameter change in chemical structure and crystal form fundamentally alters the pharmacokinetic profile, expanding the therapeutic window and reducing toxicity while maintaining therapeutic efficacy.
Solution Approach 2:
The invention creates composite crystalline materials by combining lithium salts with specific organic acids in defined stoichiometric ratios. These composite co-crystal structures exhibit improved stability and controlled release characteristics that reduce peak blood concentrations and associated toxicity.
2Reliability
If current lithium treatments are administered, then therapeutic effect is achieved, but blood lithium concentrations peak sharply leading to high toxicity
Solution Approach 1:
The novel crystalline lithium compounds provide more sustained and periodic release of lithium ions rather than sharp peaks. The controlled release mechanism maintains steadier blood concentrations over time, reducing the harmful sharp peaks while maintaining continuous therapeutic effect.
Solution Approach 2:
The organic acid components act as intermediaries that modulate the release and transport of lithium ions. These intermediary molecules control the dissolution and absorption kinetics, preventing sharp concentration peaks while ensuring adequate brain bioavailability.
3Reliability
If high doses of lithium are administered to overcome low brain bioavailability, then brain penetration is improved, but toxicity increases
Solution Approach 1:
The patent changes the physicochemical parameters of lithium compounds to improve blood-brain barrier penetration. The novel crystalline forms exhibit enhanced solubility and membrane permeability characteristics that increase brain bioavailability at lower doses, avoiding the toxicity associated with high dosing.
4Adaptability or versatility
If many lithium containing compounds are used, then alternative therapeutic sources are available, but the compounds are hygroscopic and unstable
Solution Approach 1:
The invention creates stable composite co-crystal materials where lithium salts are combined with hygroscopic-resistant organic acids. This composite structure protects the lithium component from moisture uptake while maintaining therapeutic efficacy, solving the hygroscopicity problem of conventional lithium compounds.
Solution Approach 2:
The patent develops stable crystalline forms that do not require stringent storage conditions or frequent replacement due to degradation. The improved stability allows longer shelf life and reduced monitoring requirements, making the therapy more practical and accessible.
Data Source
AI summary
Stable crystal forms comprising lithium ions and the conjugate base of an organic acid which is in the form of anhydrous coordination polymer that exhibit improved in vivo performance with respect to lithium carbonate.